重庆康刻尔制药股份有限公司
Clinical Trials
0
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
26
NMPA:26
Drug Approvals
Glipizide Orally Disintegrating Tablets
- Product Name
- 格列吡嗪口腔崩解片
- Approval Number
- 国药准字H20080395
- Approval Date
- Jun 9, 2023
NMPA
Loratadine Orally Disintegrating Tablets
- Product Name
- 伉尔纾坦
- Approval Number
- 国药准字H20080294
- Approval Date
- Jan 3, 2023
NMPA
Valsartan and Hydrochlorothiazide Capsules
- Product Name
- 缬沙坦氢氯噻嗪胶囊
- Approval Number
- 国药准字H20080097
- Approval Date
- Oct 28, 2022
NMPA
Zaleplon Orally Disintegrating Tablets
- Product Name
- 扎来普隆口腔崩解片
- Approval Number
- 国药准字H20110071
- Approval Date
- May 12, 2021
NMPA
Ambroxol Hydrochloride Orally Disintegrating Tablets
- Product Name
- 康尔可通
- Approval Number
- 国药准字H20060910
- Approval Date
- May 12, 2021
NMPA
Salbutamol Sulfate Orally Disintegrating Tablets
- Product Name
- 康尔贝宁
- Approval Number
- 国药准字H20041376
- Approval Date
- Sep 15, 2020
NMPA
- Prev
- 1
- 2
- 3
- Next
Clinical Trials
No trials found
News
No news found